More on Teva Pharmaceutical
- Teva Vs. Viatris: Who Will Dominate In President Trump’s America?
- Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside
- Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors
- Teva gains after Q3 beat and guidance hike
- Teva Pharmaceutical Non-GAAP EPS of $0.78 beats by $0.11, revenue of $4.48B beats by $150M